Item 7.01 Regulation FD Disclosure. On April 8, 2026, STAAR Surgical Company (the “ Company”) issued a press release reporting selected preliminary financial results for the first quarter ended April 3, 2026, a copy of the Press Release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by this reference. The Company expects to report its full first quarter financial results in early May 2026. The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report, and Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release of the Company dated April 8, 2026. ───────────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STAAR Surgical Company April 8, 2026 /s/ DEBORAH ANDREWS Deborah Andrews Interim Co-Chief Executive Officer and Chief Financial Officer